Immunizations received by each patient
| Patient . | Before rituximab treatment . | After rituximab treatment . | ||
|---|---|---|---|---|
| Primary antigen . | Recall antigen . | Primary antigen . | Recall antigen . | |
| A | HAV | PV | * | TT |
| B | † | TT | KLH | PV |
| C | * | TT | HAV | PV |
| D | HAV1-155 | TT | KLH | PV |
| E | * | TT | ‡ | ‡ |
| F | KLH | PV | HAV1-155 | TT |
| G | HAV1-155 | TT | KLH | PV |
| H | HAV1-155 | PV | 1-153 | 1-153 |
| I | KLH | PV | HAV1-155 | TT |
| J | KLH | TT | HAV | PV |
| K | HAV | PV | KLH | TT |
| Patient . | Before rituximab treatment . | After rituximab treatment . | ||
|---|---|---|---|---|
| Primary antigen . | Recall antigen . | Primary antigen . | Recall antigen . | |
| A | HAV | PV | * | TT |
| B | † | TT | KLH | PV |
| C | * | TT | HAV | PV |
| D | HAV1-155 | TT | KLH | PV |
| E | * | TT | ‡ | ‡ |
| F | KLH | PV | HAV1-155 | TT |
| G | HAV1-155 | TT | KLH | PV |
| H | HAV1-155 | PV | 1-153 | 1-153 |
| I | KLH | PV | HAV1-155 | TT |
| J | KLH | TT | HAV | PV |
| K | HAV | PV | KLH | TT |
No KLH immunization was performed because of logistics problems at the initiation of the immunization study.
Patient was known to be HAV-seropositive; therefore, HAV immunization was not performed.
No immunizations were performed after rituximab treatment because of non–study-related disease.
No immunizations were performed after rituximab treatment because of logistics problems.
These patients were found later to be HAV-seropositive.